Is it Apt to Hold Edwards Lifesciences Stock in Your Portfolio Now?

Zacks12-13

Edwards Lifesciences EW, following the sell-off of the Critical Care wing, looks forward to developing the most comprehensive structural heart portfolio. In TMTT, the robust adoption of the ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2491377510?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/B7EfA6ERTo_QO90H15uyXw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0","is_english":true,"pubTime":"2024-12-13 22:14","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2491377510","market":"us","top_or_hot":-1,"title":"Is it Apt to Hold Edwards Lifesciences Stock in Your Portfolio Now?","media":"Zacks","content":"<div>\n<p>Edwards Lifesciences EW, following the sell-off of the Critical Care wing, looks forward to developing the most comprehensive structural heart portfolio. In TMTT, the robust adoption of the ...</p>\n\n<a href=\"https://finance.yahoo.com/news/apt-hold-edwards-lifesciences-stock-141400725.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is it Apt to Hold Edwards Lifesciences Stock in Your Portfolio Now?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs it Apt to Hold Edwards Lifesciences Stock in Your Portfolio Now?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-13 22:14 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/apt-hold-edwards-lifesciences-stock-141400725.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Edwards Lifesciences EW, following the sell-off of the Critical Care wing, looks forward to developing the most comprehensive structural heart portfolio. In TMTT, the robust adoption of the ...</p>\n\n<a href=\"https://finance.yahoo.com/news/apt-hold-edwards-lifesciences-stock-141400725.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PEN","symbol_name":"Penumbra Inc","start_time":0,"source_url":"https://finance.yahoo.com/news/apt-hold-edwards-lifesciences-stock-141400725.html","article_id":"2491377510","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/B7EfA6ERTo_QO90H15uyXw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2491377510","pubTimestamp":1734099240,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Edwards LifesciencesEW, following the sell-off of the Critical Care wing, looks forward to developing the most comprehensive structural heart portfolio. In TMTT, the robust adoption of the differentiated PASCAL technology is highly promising. The company is also advancing toward long-term growth through several initiatives across its businesses. Meanwhile, adverse macroeconomic impacts and currency fluctuations remain a concern for Edwards.In the past year, this Zacks Rank #3  stock has dropped 1.6% against the industry’s 9.6% rise and the S&P 500 composite’s 30.5% growth.The renowned global medical device company has a market capitalization of $43.53 billion. EW’s earnings surpassed estimates in one of the trailing four quarters and matched on three occasions, the average surprise of 0.78%.Long-Term Growth Strategy Buoys Optimism: Edwards Lifesciences expects to maintain its leadership position in the global TAVR market by developing next-generation valve platforms and maintaining tru","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"PEN":"Penumbra Inc","LU0122379950.USD":"贝莱德世界健康科学A2","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU0251132253.USD":"FIDELITY FUNDS  GLOBAL THEMATIC OPPORTUNITIES \"A\" (USD) ACC","LU2506951875.HKD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"CRH\" (HKDHDG) ACC","LU0345769631.USD":"NINETY ONE GSF GLOBAL EQUITY \"A\" (USD) INC","LU1718418525.SGD":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD","BK4581":"高盛持仓","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU2242649171.HKD":"FIDELITY FUNDS GLOBAL THEMATIC OPPORTUNITIES \"A\" (HKD) ACC","LU2506952097.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"CRH\" (USDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","BK4504":"桥水持仓","LU2506951958.HKD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"CRH\" (HKDHDG) INC","LU0077335932.USD":"FIDELITY AMERICAN GROWTH \"A\" INC","LU0205193047.USD":"SCHRODER ISF US SMALL & MID-CAP EQUITY \"A\" (USD)  ACC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","BK4548":"巴美列捷福持仓","LU1989764748.USD":"东方汇理环球颠覆性机遇A2 Acc","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU2491049909.HKD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (HKD) ACC","LU0528227936.USD":"富达环球人口趋势基金A-ACC","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU2491050071.SGD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (SGDHDG) ACC","LU1791710582.SGD":"Fidelity Global Demographics A-ACC-SGD (SGD/USD hedged)","LU0187121727.USD":"FIDELITY SUSTAINABLE US EQUITY \"A\" (USD) INC","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","LU2491050154.USD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (USD) ACC","EW":"爱德华兹","LU1791710400.SGD":"Fidelity Global Demographics A-ACC-SGD","LU0048584097.USD":"FIDELITY FUNDS  GLOBAL THEMATIC OPPORTUNITIES \"A\" (USD) INC","LU0353189680.USD":"富国美国全盘成长基金Cl A Acc","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU0238689110.USD":"贝莱德环球动力股票基金","BSX":"波士顿科学","LU1804176565.USD":"EASTSPRING INV GLOBAL GROWTH EQUITY \"A\" (USD) ACC","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","LU0106261612.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" ACC","LU0011850046.USD":"贝莱德全球长线股票 A2 USD","HAE":"美国血液技术","LU0823417737.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"C\" (USD) INC","BK4588":"碎股","BK4198":"医疗保健用品","LU0882574055.USD":"富达全球健康医疗A ACC","LU0012050646.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" (USD) INC AV","AR":"Antero Resources Corp"},"translate_title":"现在在您的投资组合中持有爱德华兹生命科学股票合适吗？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PEN":1,"AR":1,"BSX":1,"EW":1,"HAE":0.9},"content_text":"Edwards Lifesciences EW, following the sell-off of the Critical Care wing, looks forward to developing the most comprehensive structural heart portfolio. In TMTT, the robust adoption of the differentiated PASCAL technology is highly promising. The company is also advancing toward long-term growth through several initiatives across its businesses. Meanwhile, adverse macroeconomic impacts and currency fluctuations remain a concern for Edwards.\nIn the past year, this Zacks Rank #3 (Hold) stock has dropped 1.6% against the industry’s 9.6% rise and the S&P 500 composite’s 30.5% growth.\nThe renowned global medical device company has a market capitalization of $43.53 billion. EW’s earnings surpassed estimates in one of the trailing four quarters and matched on three occasions, the average surprise of 0.78%.\nLet’s delve deeper.\nUpsides for EW\nCritical Care Divestment Fuels Structural Heart Opportunities: On Sept. 3, 2024, Edwards Lifesciences completed the sale of its Critical Care product group to Becton, Dickinson and Company for $4.2 billion in an all-cash transaction. Edwards expects this sell-off to enhance the company’s balance sheet flexibility for disciplined investments in technologies for aortic, mitral, tricuspid and pulmonic patients and new therapeutic areas for interventional heart failure. The company’s underlying rationale for separating Critical Care aligns with its vision to develop the most comprehensive structural heart disease portfolio.\nThrough its differentiated innovations, Edwards aims to address large unmet patient needs while extending its global leadership, delivering sustainable growth and increasing shareholder value.\nImage Source: Zacks Investment Research\nTMTT Portfolio Holds Potential: Backed by the insights gained from clinical trials and real-world experiences, Edwards Lifesciences constructed a strategic portfolio of leading transcatheter technologies to provide repair and replacement solutions for mitral and tricuspid patients.In the third quarter of 2024, the segment achieved a 73% increase versus the prior year. The adoption of differentiated PASCAL technology is expanding in both new and existing sites worldwide. Globally, mitral procedures are experiencing double-digit growth and even stronger growth in tricuspid therapy.\nThe company is making strides with the EVOQUE commercial rollout, successfully activating new sites in the United States and Europe (other than initial trial centers). During the third quarter, the company achieved approval in the United States for a fourth and larger size EVOQUE valve — 56 millimeters. Also, EVOQUE became eligible for Medicare's new technology add-on payment in October.\nLong-Term Growth Strategy Buoys Optimism: Edwards Lifesciences expects to maintain its leadership position in the global TAVR market by developing next-generation valve platforms and maintaining trusted relationships with clinicians, payers and regulators. The company is leading several global initiatives, including reaching more patients through patient awareness, activation and access and enhancing physician training and support programs.\nFor TMTT, key initiatives undertaken for long-term growth include broadening the launch of PASCAL, advancing the introduction of EVOQUE in the United States and Europe and launching SAPIEN M3 in Europe next year. Moreover, the company plans to enter new therapeutic areas, such as aortic regurgitation (AR) and implantable heart failure management (IHFM). Having completed enrollments in the United States and Canada a year ahead of the plan, the MOMENTIS clinical study will continue to open new sites in Europe and Latin America, with global enrollment continuing into 2025.\nConcerns for Edwards\nMacro Concerns Put Pressure on the Bottom Line: The global economy continues to experience volatility and disruptions, including inflation and factors influencing overall economic stability and the political environment relating to health care. Any significant increases in the cost of raw materials, led by inflationary pressure, supply constraints stemming from geopolitical complications, regulatory changes or otherwise, could weigh heavily on the company’s operating results. Post the pandemic, the business is currently experiencing staffing shortages within the hospital systems. \nForeign Exchange Headwinds: Foreign exchange is a major headwind for Edwards Lifesciences due to a considerable percentage of its revenues coming from outside the United States. We remain worried about the significant challenges Edward Lifesciences had to face owing to the unfavorable foreign currency impact that has adversely affected the company’s gross margin over the past few quarters.\nEW Stock Estimate Trends\nThe Zacks Consensus Estimate for Edwards Lifesciences’ 2024 earnings per share (EPS) has fallen 2 cents to $2.56 in the past 30 days.\nThe Zacks Consensus Estimate for the company’s 2024 revenues is pegged at $5.82 billion, down 3.1% from the year-ago reported number.\nKey Picks\nSome better-ranked stocks in the broader medical space are Haemonetics HAE, Boston Scientific BSX and Penumbra PEN.\nHaemonetics has an earnings yield of 5.41% compared with the industry’s 1.75%. Haemonetics’ earnings surpassed the Zacks Consensus Estimate in three of the trailing four quarters and missed on one occasion, the average surprise being 2.82%. Its shares have risen 8.9% compared with the industry’s 21.2% growth in the past year.\nHAE carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.\nBoston Scientific, carrying a Zacks Rank #2 at present, has a long-term estimated earnings growth rate of 13.8%. Shares of the company have surged 63.4% compared with the industry’s 23.1% growth. BSX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.29%.\nPenumbra, carrying a Zacks Rank #2 at present, has an estimated earnings growth rate of 35.3% for 2024 compared with the industry’s 12.8%. Shares of Penumbra have risen 7.8% compared with the industry’s 15.1% growth over the past year. PEN’s earnings surpassed estimates in three of the trailing four quarters and missed in one, the average surprise being 10.54%.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nBoston Scientific Corporation (BSX) : Free Stock Analysis Report\nEdwards Lifesciences Corporation (EW) : Free Stock Analysis Report\nHaemonetics Corporation (HAE) : Free Stock Analysis Report\nPenumbra, Inc. (PEN) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2491377510"}